New fungal infections associated with disease-modifying treatments in MS

Abstract

Keywords

Natalizumab dimethyl fumarate

Get full access to this article

View all access options for this article.

References

Farber

Harel

Lublin

. Novel agents for relapsing forms of multiple sclerosis. Annu Rev Med 2016; 67: 309–321.

Almeida

Barreto-Soares

Campos-Sausa

et al . Pulmonary paracoccidioidomycosis associated with use of natalizumab in multiple sclerosis. Multiple Scler J, this issue.

Greenstein

. Diffuse dermatophytosis occurring on dimethylfumarate therapy. Multiple Scler J, this issue.

Linker

Lee

Ryan

et al . Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011; 134: 678–692.

Dubey

Kieseier

Hartung

et al . Dimethyl fumarate in relapsing-remitting multiple sclerosis: Rationale, mechanisms of action, pharmacokinetics, efficacy and safety. Expert Rev Neurother 2015; 15: 339–346.

Yednock

Cannon

Fritz

et al . Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356: 63–66.

Nino

Bodner

Simard

et al . Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 2006; 59: 748–754.

Romani

. Immunity to fungal infections. Nature Rev Immunol 2011; 11: 275–288.

Hau

Tada

Kanda

et al . Immunoresponses in dermatomycoses. J Dermatol 2015; 42: 236–244.

10.

Jaradat

Cubillos

Krieg

et al . Low DEFB4 copy number and high systemic HBD-2 and IL-22 levels are associated with dermatophytosis. J Invest Dermathol 2015; 135: 750–758.

11.

Shikanai-Yasuda

Mendes

Lopes Colombo

et al . Brazilian guidelines for the clinical management of paracoccidioidomycosis. Rev Soc Bras Med Trop 2017; 50: 715–740.

12.

McGinley

Moss

Cohen

. Safety monoclonal antibodies for the treatment of multiple sclerosis. Expert Opin Drug Saf 2017; 16: 89–100.